Memaben (Memantine Hydrochloride)

Memaben is an NMDA receptor antagonist used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

• Alzheimer’s disease (mild to moderate): improves cognitive performance and daily living activities.
• Alzheimer’s disease (moderate): helps maintain functional abilities and slows symptomatic decline.
• Alzheimer’s disease (as adjunct to cholinesterase inhibitors): provides additional symptomatic benefit when combined with standard therapy.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by glutamate over‑activation, thereby limiting excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memaben may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Confusion: temporary disorientation.
• Fatigue: feeling unusually tired.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Hallucinations: visual or auditory disturbances.
• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Before initiating Memaben, several safety considerations should be reviewed.

• Renal impairment: assess kidney function and adjust therapy if necessary.
• History of seizures: monitor closely for increased seizure activity.
• Concurrent NMDA agonists: avoid use as they may counteract therapeutic effect.
• Pregnancy: prescribe only when potential benefit justifies potential risk to the fetus.
• Elderly patients: watch for heightened confusion or falls.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memaben can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Amantadine: may diminish memantine’s therapeutic effect.
• Ketamine: additive NMDA antagonism could increase neuro‑psychiatric adverse events.
• Mefenamic acid: may heighten dizziness and hypotension.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may worsen cognitive impairment.
• Central nervous system depressants (e.g., benzodiazepines): can enhance sedation and dizziness.